KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Net Cash Flow (2016 - 2025)

AbbVie (ABBV) has disclosed Net Cash Flow for 14 consecutive years, with -$411.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Cash Flow rose 75.64% to -$411.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$337.0 million, a 95.34% increase, with the full-year FY2025 number at -$337.0 million, up 95.34% from a year prior.
  • Net Cash Flow was -$411.0 million for Q4 2025 at AbbVie, up from -$830.0 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $5.3 billion in Q1 2024 to a low of -$5.9 billion in Q3 2024.
  • A 5-year average of -$152.2 million and a median of -$453.5 million in 2023 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: tumbled 552.63% in 2021, then soared 311.01% in 2024.
  • AbbVie's Net Cash Flow stood at -$2.4 billion in 2021, then dropped by 10.22% to -$2.7 billion in 2022, then surged by 81.31% to -$496.0 million in 2023, then tumbled by 240.12% to -$1.7 billion in 2024, then surged by 75.64% to -$411.0 million in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Net Cash Flow are -$411.0 million (Q4 2025), -$830.0 million (Q3 2025), and $1.3 billion (Q2 2025).